Growth Opportunities in the Western European Oncology Diagnostics Market, Forecast to 2021

Growth Opportunities in the Western European Oncology Diagnostics Market, Forecast to 2021

Data-driven Solutions and Co-development are Key Growth Drivers

RELEASE DATE
30-Jun-2017
REGION
Europe
Research Code: MD29-01-00-00-00
SKU: HC02837-EU-MT_20323

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC02837-EU-MT_20323

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer.

The oncology diagnostics market is experiencing consolidation between the major pharma and diagnostic participants who are collaborating to devise and implement disruptive technologies for cancer diagnosis. The research focuses on highlighting some of the major trends occurring in the market alongside these strategic partnerships. Furthermore, emphasis is on the key challenges in the European market in terms of regulations pertaining to companion diagnostics for cancer detection and monitoring. The deliverable outlines some of the major drivers and restraints, impact analysis of major growth opportunities, as well as market engineering measurements.

With early detection being a key imperative in oncology diagnosis, the study highlights some of the major technology trends in the market with the application of Artificial Intelligence and Big Data as well as Liquid Biopsy and Next Generation Sequencing, which are expected to reduce the turnaround time for cancer detection, thus speeding up the treatment uptake. Emphasis is given to the emerging biomarkers across the types of cancer, which are expected to aid in faster and easier diagnosis of the disease. Furthermore, analysis is provided for the key participants that are working towards devising new solutions which help to detect these biomarkers, thereby supporting accurate detection and monitoring. In addition to the key participants across the market, new market entrants by different cancer types have been profiled.

Some of the key questions answered by the study include:
•     How is the market attractiveness for oncology diagnostics building up over the years? What is the future market potential?
•     How is the adoption of technology affecting the European oncology diagnostic market?
•     Which are the disruptions affecting the value chain equilibrium?
•     How are the new technology trends impacting service providers?
•     How is the changing economic scenario affecting the regional market? Which are the most opportune markets in Europe?
•     What is the application of companion diagnostics on the overall market? How is it expected to impact the market over the next few years?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Purpose of this Experiential Study

5-Step Process to Transformational Growth

Strategic Imperatives for Oncology Diagnostics Market

Scope and Segmentation

Market Engineering Measurements

Big Market Themes

Methodology

Industry Ecosystem

Key Trends and Impact on Business

Market Drivers and Restraints

Industry Challenges

Legislative Framework for Genetic Testing in EU5

Market Engineering Measurements

Revenue Forecast by Cancer Type

Segmentation by Technology and Function

Breast Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Breast Cancer Diagnostics

Country-wise Highlights

Segmentation by Technology and Function

Ovarian Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Ovarian Cancer Diagnostics

Country-wise Highlights

Segmentation by Technology and Function

Cervical Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Cervical Cancer Diagnostics

Country-wise Highlights

Segmentation by Technology and Function

Prostate Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Prostate Cancer Diagnostics

Country-wise Highlights

Segmentation by Technology and Function

Lung Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Lung Cancer Diagnostics

Country-wise Highlights

Segmentation by Technology and Function

Colorectal Cancer Diagnostic Pathway

Revenue Forecast by Country

Revenue Forecast by Technology

Competitor Scenario and Market Share Analysis

Key Companies to Watch

Emerging Technologies in Colorectal Cancer Diagnostics

Country-wise Highlights

EU Competitive Landscape by Technology

Competitive Environment

Competitive Factors and Assessment

Competitive Playbook—Key Market Participants by Country

Key M&A Assessment

Oncology Diagnostics Market—Macro to Micro Visioning

Companion Diagnostics—Reimbursement Overview across Western Europe

Companion Diagnostics—Reimbursement Challenges

Companion Diagnostics—An Opportunity

Liquid Biopsy—A Step Ahead in Biomarker Analysis

Recent Events in Liquid Biopsy Segment

Top 3 Predictions for the Market

5 Major Growth Opportunities

Growth Opportunities Impact Analysis

Growth Opportunity 1—Artificial Intelligence (AI)

Growth Opportunity 2—Real-time Diagnostics

Growth Opportunity 3—Genetic Testing and Biomarkers

Growth Opportunity 4—Point-of-care Testing

Growth Opportunity 5—Next Generation Sequencing (NGS)

The Last Word

Legal Disclaimer

List of Abbreviations

List of Figures
  • 1. Total Oncology Diagnostics Market: Industry Ecosystem, Europe, 2016
  • 2. Total Oncology Diagnostics Market: Market Drivers and Restraints, W. Europe, 2017–2021
  • 3. Total Oncology Diagnostics Market: Industry Challenges, W. Europe, 2017–2021
  • 4. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016
  • 5. Breast Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 6. Breast Cancer Diagnostics Segment: Key Companies to Watch, Breast Cancer, Europe, 2016
  • 7. Breast Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 8. Breast Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 9. Ovarian Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 10. Ovarian Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
  • 11. Ovarian Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 12. Ovarian Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 13. Cervical Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 14. Cervical Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
  • 15. Cervical Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 16. Cervical Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 17. Prostate Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 18. Prostate Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
  • 19. Prostate Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 20. Prostate Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 21. Lung Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 22. Lung Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
  • 23. Lung Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 24. Lung Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 25. Colorectal Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016
  • 26. Colorectal Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016
  • 27. Colorectal Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016
  • 28. Colorectal Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016
  • 29. Total Oncology Diagnostics Market: Competitive Landscape, W. Europe, 2016
  • 30. Total Oncology Diagnostics Market: Competitive Structure, W. Europe, 2016
  • 31. Total Oncology Diagnostics Market: Trends in Importance Level of Key Competitive Factors, W. Europe, 2016
  • 32. Total Oncology Diagnostics Market: Country-wise Players, W. Europe, 2016
  • 33. Total Oncology Diagnostics Market: Key M&A Assessment, W. Europe, 2016
  • 34. Total Oncology Diagnostics Market: Companion Diagnostics—Altering Business Models, Europe, 2016
  • 35. Total Oncology Diagnostics Market: Recent Events in Liquid Biopsy Segment, W. Europe, 2016
  • 36. Total Oncology Diagnostics Market: Major Growth Opportunities, W. Europe, 2016–2021
  • 37. Total Oncology Diagnostics Market: Impact Analysis of Key Growth Opportunities, W. Europe, 2016–2021
List of Charts
  • 1. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016
  • 2. Total Oncology Diagnostics Market: Key Trends and Impact on Business, W. Europe, 2016
  • 3. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Type, W. Europe, 2013–2021
  • 4. Breast Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 5. Breast Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 6. Breast Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
  • 7. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 8. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 9. Ovarian Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
  • 10. Cervical Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 11. Cervical Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 12. Cervical Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
  • 13. Prostate Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 14. Prostate Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 15. Prostate Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016
  • 16. Lung Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 17. Lung Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 18. Lung Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016
  • 19. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021
  • 20. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021
  • 21. Colorectal Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016
Related Research
The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer. The oncology diagnostics market is experiencing consolidation between the major pharma and diagnostic participants who are collaborating to devise and implement disruptive technologies for cancer diagnosis. The research focuses on highlighting some of the major trends occurring in the market alongside these strategic partnerships. Furthermore, emphasis is on the key challenges in the European market in terms of regulations pertaining to companion diagnostics for cancer detection and monitoring. The deliverable outlines some of the major drivers and restraints, impact analysis of major growth opportunities, as well as market engineering measurements. With early detection being a key imperative in oncology diagnosis, the study highlights some of the major technology trends in the market with the application of Artificial Intelligence and Big Data as well as Liquid Biopsy and Next Generation Sequencing, which are expected to reduce the turnaround time for cancer detection, thus speeding up the treatment uptake. Emphasis is given to the emerging biomarkers across the types of cancer, which are expected to aid in faster and easier diagnosis of the disease. Furthermore, analysis is provided for the key participants that are working towards devising new solutions which help to detect these biomarkers, thereby supporting accurate detection and monitoring. In addition to the key participants across the market, new market entrants by different cancer types have been profiled. Some of the key questions answered by the study include: • How is the market attractiveness for oncology dia
More Information
No Index No
Podcast No
Table of Contents | Executive Dashboard~ || Purpose of this Experiential Study~ || 5-Step Process to Transformational Growth~ || Strategic Imperatives for Oncology Diagnostics Market~ || Scope and Segmentation~ || Market Engineering Measurements~ || Big Market Themes~ | Growth Environment—Market Overview~ || Methodology~ || Industry Ecosystem~ || Key Trends and Impact on Business~ || Market Drivers and Restraints~ || Industry Challenges~ || Legislative Framework for Genetic Testing in EU5~ | Growth Environment—Total Oncology Diagnostics Market Forecasts~ || Market Engineering Measurements~ || Revenue Forecast by Cancer Type~ | Growth Environment—Breast Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Breast Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Breast Cancer Diagnostics~ || Country-wise Highlights~ | Ovarian Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Ovarian Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Ovarian Cancer Diagnostics~ || Country-wise Highlights~ | Cervical Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Cervical Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Cervical Cancer Diagnostics~ || Country-wise Highlights~ | Prostate Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Prostate Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Prostate Cancer Diagnostics~ || Country-wise Highlights~ | ~ | Lung Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Lung Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Lung Cancer Diagnostics~ || Country-wise Highlights~ | Colorectal Cancer Diagnostics Segment~ || Segmentation by Technology and Function~ || Colorectal Cancer Diagnostic Pathway~ || Revenue Forecast by Country~ || Revenue Forecast by Technology~ || Competitor Scenario and Market Share Analysis~ || Key Companies to Watch~ || Emerging Technologies in Colorectal Cancer Diagnostics~ || Country-wise Highlights~ | Growth Competitive Playbook~ || EU Competitive Landscape by Technology~ || Competitive Environment~ || Competitive Factors and Assessment~ || Competitive Playbook—Key Market Participants by Country~ || Key M&A Assessment~ | Visioning Scenarios~ || Oncology Diagnostics Market—Macro to Micro Visioning~ | Future Outlook and Emerging Opportunities—CDx, Liquid Biopsy, and NGS~ || Companion Diagnostics—Reimbursement Overview across Western Europe~ || Companion Diagnostics—Reimbursement Challenges~ || Companion Diagnostics—An Opportunity~ || Liquid Biopsy—A Step Ahead in Biomarker Analysis~ || Recent Events in Liquid Biopsy Segment~ || Top 3 Predictions for the Market~ | Growth Pipeline—Growth Opportunities~ || 5 Major Growth Opportunities~ || Growth Opportunities Impact Analysis~ || Growth Opportunity 1—Artificial Intelligence (AI)~ || Growth Opportunity 2—Real-time Diagnostics~ || Growth Opportunity 3—Genetic Testing and Biomarkers~ || Growth Opportunity 4—Point-of-care Testing~ || Growth Opportunity 5—Next Generation Sequencing (NGS)~ | The Last Word~ || The Last Word~ || Legal Disclaimer~ | Appendix~ || List of Abbreviations~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Total Oncology Diagnostics Market: Industry Ecosystem, Europe, 2016~ 2. Total Oncology Diagnostics Market: Market Drivers and Restraints, W. Europe, 2017–2021~ 3. Total Oncology Diagnostics Market: Industry Challenges, W. Europe, 2017–2021~ 4. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016~ 5. Breast Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 6. Breast Cancer Diagnostics Segment: Key Companies to Watch, Breast Cancer, Europe, 2016~ 7. Breast Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 8. Breast Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 9. Ovarian Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 10. Ovarian Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016~ 11. Ovarian Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 12. Ovarian Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 13. Cervical Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 14. Cervical Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016~ 15. Cervical Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 16. Cervical Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 17. Prostate Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 18. Prostate Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016~ 19. Prostate Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 20. Prostate Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 21. Lung Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 22. Lung Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016~ 23. Lung Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 24. Lung Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 25. Colorectal Cancer Diagnostics Segment: Segmentation by Technology and Function, W. Europe, 2016~ 26. Colorectal Cancer Diagnostics Segment: Key Companies to Watch, W. Europe, 2016~ 27. Colorectal Cancer Diagnostics Segment: Emerging Technologies, W. Europe, 2016~ 28. Colorectal Cancer Diagnostics Segment: Country-wise Highlights, W. Europe, 2016~ 29. Total Oncology Diagnostics Market: Competitive Landscape, W. Europe, 2016~ 30. Total Oncology Diagnostics Market: Competitive Structure, W. Europe, 2016~ 31. Total Oncology Diagnostics Market: Trends in Importance Level of Key Competitive Factors, W. Europe, 2016~ 32. Total Oncology Diagnostics Market: Country-wise Players, W. Europe, 2016~ 33. Total Oncology Diagnostics Market: Key M&A Assessment, W. Europe, 2016~ 34. Total Oncology Diagnostics Market: Companion Diagnostics—Altering Business Models, Europe, 2016~ 35. Total Oncology Diagnostics Market: Recent Events in Liquid Biopsy Segment, W. Europe, 2016~ 36. Total Oncology Diagnostics Market: Major Growth Opportunities, W. Europe, 2016–2021~ 37. Total Oncology Diagnostics Market: Impact Analysis of Key Growth Opportunities, W. Europe, 2016–2021~| 1. Total Oncology Diagnostics Market: Market Engineering Measurements, W. Europe, 2016~ 2. Total Oncology Diagnostics Market: Key Trends and Impact on Business, W. Europe, 2016~ 3. Total Oncology Diagnostics Market: Revenue Forecast by Cancer Type, W. Europe, 2013–2021~ 4. Breast Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 5. Breast Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 6. Breast Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016~ 7. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 8. Ovarian Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 9. Ovarian Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016~ 10. Cervical Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 11. Cervical Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 12. Cervical Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016~ 13. Prostate Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 14. Prostate Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 15. Prostate Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016~ 16. Lung Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 17. Lung Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 18. Lung Cancer Diagnostics Segment: Market Share Analysis, W. Europe, 2016~ 19. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Country, W. Europe, 2013–2021~ 20. Colorectal Cancer Diagnostics Segment: Revenue Forecast by Technology, W. Europe, 2013–2021~ 21. Colorectal Cancer Diagnostics Segment: Market Share Analysis, Europe, 2016~ 22.
Author Aarti Chitale
Industries Healthcare
WIP Number MD29-01-00-00-00
Is Prebook No